TOPOTECANE ACCORD 1 mg/ml

DRUG3 trials

Sponsors

Pfizer Inc., Institut Curie, Glaxosmithkline Research & Development Limited

Conditions

LungNeoplasmsOcular conservative treatment for retinoblastomarecurrent or refractory neuroblastomarecurrent/refractory Ewing sarcoma

Phase 1

A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

CompletedCTIS2024-511975-14-00

Pfizer Inc.recurrent or refractory neuroblastoma, recurrent/refractory Ewing sarcoma

Start: 2022-05-26End: 2025-08-06Target: 29Updated: 2025-09-08

Phase 2

RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome

RecruitingCTIS2024-514025-30-00

Institut CurieOcular conservative treatment for retinoblastoma

Start: 2021-03-25Target: 225Updated: 2024-05-31

Phase 3

Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC)

Not yet recruitingCTIS2025-521627-78-00

Glaxosmithkline Research & Development LimitedLung, Neoplasms

Target: 161Updated: 2026-01-26